Group 1 - The company held its 22nd meeting of the fifth board of directors on December 24, 2025, where all five directors attended, and the meeting complied with relevant laws and regulations [2][4]. - The board approved the proposal not to adjust the conversion price of the convertible bonds, "Meinuo Convertible Bonds" [3][5]. - The decision was made despite the stock price being below the conversion price threshold, which triggered the adjustment clause [9][16]. Group 2 - As of December 24, 2025, the company's stock had closed below 90% of the current conversion price (25.68 CNY/share) for at least 15 out of the last 30 trading days, indicating a potential adjustment [9][16]. - The next period for triggering the conversion price adjustment clause will restart from December 25, 2025, and the board will decide on any future adjustments if triggered again [9][16]. - The initial conversion price of the "Meinuo Convertible Bonds" was set at 37.47 CNY/share, with subsequent adjustments made over time due to various corporate actions [10][11].

证券日报网12月24日讯 ，诚达药业在12月24日回答调研者提问时表示，公司募投项目产能逐渐释放， 能满足客户不同产品、不同阶段、不同规模订单的需求。 （文章来源：证券日报） ...

证券日报网12月24日讯 ，诚达药业在12月24日回答调研者提问时表示，公司具备稳定有效的质量体 系、生产特定产品所需要的设备和技术、供应链的顺畅和反应速度以及EHS和合规性等优势。同时公司 相关产品通过了中国NMPA、美国FDA、日本PMDA、韩国MFDS、意大利AIFA、英国MHRA、加拿大 HC、希腊等国家药政管理部门的审评，并取得了欧洲CEP认证证书，覆盖了全球主流市场的质量体系 认证，产品质量得到了客户的广泛认可。 （编辑 姚尧） ...

Group 1 - The core business of the company currently focuses on small nucleic acids, specifically phosphoramidite monomers and GalNAc delivery systems [1] - The pricing for different monomers and delivery systems varies, with delivery systems being priced higher than monomers [1]

Group 1 - The company announced an investment of 85 million yuan in a structured deposit with a floating return from Industrial Bank's Tianjin branch, with an expected annual yield of 1.20%-1.60% [2] - As of the announcement date, the company has a cash management balance of 155 million yuan, which is below the authorized limit of 600 million yuan [2]

（文章来源：证券日报） 证券日报网讯 12月24日，润都股份在互动平台回答投资者提问时表示，公司1类创新药盐酸去甲乌药碱 注射液（规格：2ml：2.5mg）及其原料药的注册审评工作正在有序推进中。公司已完成药学补充研究 并于2025年4月提交资料（此次发补，无临床相关内容）。根据《国家药品监督管理局药品审评过程中 审评计时中止与恢复管理规范（试行）》（药审业〔2022〕614号）规定，药品审评存在多种审评计时 中止情形，中止期间所占时间不计入审评时限。当前该药品处于药学审评序列暂停阶段，属于审评流程 中的正常情况。后续如有重大进展，公司将严格遵循信息披露规定及时履行披露义务。 ...

Core Viewpoint - Kangchen Pharmaceutical has received FDA approval for the clinical trial of its drug KC1086, a small molecule inhibitor targeting KAT6, which is intended for the treatment of advanced recurrent or metastatic solid tumors [1][2]. Group 1: Drug Development and Approval - The FDA has issued a "Study May Proceed" notification for the clinical trial application of KC1086, allowing the company to advance its research [1]. - KC1086 is a novel, highly selective small molecule inhibitor of Lysine Acetyltransferase 6 (KAT6), developed entirely by Kangchen Pharmaceutical [1]. Group 2: Mechanism and Clinical Relevance - KAT6 is part of the MYST family of histone acetyltransferases and plays a crucial role in transcription regulation, development, hematopoietic cell differentiation, cell cycle progression, and mitosis [1]. - Abnormal high expression of KAT6 has been linked to various cancers, including breast, ovarian, cervical, lung adenocarcinoma, colon and rectal adenocarcinoma, and medulloblastoma, indicating its relevance in tumorigenesis and poor prognosis [1]. Group 3: Efficacy in Preclinical Models - KC1086 has demonstrated excellent in vivo efficacy in various mouse xenograft models, achieving over 90% tumor inhibition in ER+/HER2- breast cancer models, with similar effects observed in other solid tumor models [2]. - The clinical trial for KC1086 is progressing systematically, with the first human clinical study expected to start by the end of June 2025, following the implied approval from the National Medical Products Administration [2].

Group 1 - The core point of the article is that Aorite (SH 605116) announced a share reduction by Tian Tai Bo En, which has completed a plan to sell 1,000,000 shares, representing 0.25% of the company's total share capital [1] - As of the announcement date, Tian Tai Bo En still holds 5,606,000 shares, which is 1.38% of the total share capital of Aorite [1] - Aorite's revenue composition for the first half of 2025 is as follows: 85.12% from self-produced raw materials and intermediates, 11.64% from formulations, 2.74% from trading, and 0.5% from other businesses [1] Group 2 - The current market capitalization of Aorite is 9.7 billion yuan [1]

格隆汇12月24日丨奥锐特(605116.SH)公布，截至本公告披露日，天台铂恩以集中竞价交易方式减持100 万股，占公司总股本的0.25%，本次减持计划已实施完毕。天台铂融恩目前仍持有公司股份560.6万股， 占公司总股本的1.38%。 ...

12月23日，北大医药（000788）披露关于仲裁事项进展的公告。 公告显示，公司于2025年12月19日收到重庆仲裁委员会送达的《重庆仲裁委员会参加仲裁通知书》及相关材料，重庆西南合成制药有限公司(以下简称"重 庆合成")向重庆仲裁委员会提出了相关仲裁请求，公司已于近日向重庆仲裁委员会提出仲裁反请求并获受理。 北大医药请求裁决对《资产转让协议》第5.5条解除后相关人员的人力成本进行清算，并由重庆合成承担相关人员在前述合同条款解除之前的工作年限对 应的经济补偿和其他解除劳动合同可能承担的费用。 北大医药提出，2015年5月，北大医药与重庆合成签订《资产转让协议》，将相关原料药业务经营性资产转让给重庆合成，并在协议第5.5条约定了原料药 业务相关人员随标的资产一并转移至重庆合成。 在该协议签订后，北大医药将约定资产全部移交给了重庆合成，自资产移交之后，相关人员的工资、社保费用等均由重庆合成实际承担。 现在，重庆合成提出解除《资产转让协议》第5.5条，该诉求系重庆合成单方面提出，该条款解除后，相关人员劳动关系转移给北大医药，而北大医药目 前无法给予适当岗位安置人员，故必然产生人员解聘的成本费用，故应当对《资产转让 ...